This led to increased sensitivity of MCF7-R cells to gemcitabine, suggesting that silencing the MTH1 gene can enhance the sensitivity of breast cancer cells, potentially serving as a novel adjuvant therapy for targeting drug-resistant tumors (Wen et al., 2021). This evidence concerns the gene NUDT1 and breast carcinoma.